Orphan Drug Development for Rare Diseases (e-book)
Table of Contents
Chapter 1 Orphan Drug Development in the US
Chapter 2 Orphan Medicine Development in the EU
Chapter 3 Orphan Medicine Development in the UK
Chapter 4 Orphan Drug Development in Japan
Chapter 5 Orphan Drug Development in Australia
Chapter 6 Orphan Drug Development in Canada
Chapter 7 Rare Disease/Orphan Drug Development in the Rest of the World
Sundar Ramanan, PhD, MBA and Sunny Kamlesh Dave, MPharm
About the Book
Available formats: e-book only
Orphan Drug Development for Rare Diseases covers every aspect of orphan drug development. Topics include history, incentives, benefits, patient engagement, orphan drug designation, marketing authorization, and market access. Real-world case studies and examples are presented.
Orphan Drug Development for Rare Diseases explores challenges facing the developer and provides strategies to overcome them. The strategies involve adopting the applicable regulatory guidance, involving patients, and reviewing precedent and case studies. Each chapter emphasizes the critical role that patients and patient advocacy groups play in each stage of orphan drug development. A number of diverse rare disease organizations are described.
The authors address how a company can reduce its financial burden in the drug development process by taking advantage of grants, involving academia, and working with patients early in the process. Orphan Drug Development for Rare Diseases presents the regulatory tools, resources, and practices for developing orphan drugs, and how to apply them.
This all-inclusive resource spans 30 countries, including ICH regions (US, EU, UK, Japan, Australia, Canada), plus 24 other countries. There are no other publicly available regulatory resources that cover every aspect of the orphan drug development process.
Who will benefit from this book?
Orphan Drug Development for Rare Diseases will be helpful for regulatory professionals at all levels. It demonstrates key learnings for those new to drug development to those seeking advanced treatments and cures for rare diseases. Academic institutions, non-profit organizations, small and large pharmaceutical companies, and pharmaceutical professionals involved in drug development also will benefit.
Understanding development and regulatory processes is crucial to advancing therapies for rare diseases, which involves complex and unique incentives, requirements, market considerations, and opportunities for patient engagement.
Purchasing Options
This book can be purchased in the following formats:
- Digital e-book. Single purchase; accessible online via RAPS Library online reader and downloadable.
This book can also be purchased as part of the following bundles:
- All Access Library (12-month digital subscription)
Published by RAPS © 2021. E-book. 160 pages. ISBN (digital): 978-1-947493-76-6.
